Fairvalue-Calculator Fairvalue-Calculator
EN DE

Biomerica, Inc (BMRA) Fair Value & Analysis

Healthcare · US · Market cap $6.1M

Price$1.75
Fair Value$0.9800
Upside-44.0%
Quality95/100
Evidence: Low Range $0.6500 – $1.23

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Biomerica, Inc (BMRA) currently trades at $1.75, while our model-based Fair Value estimate is $0.9800 — implying the stock looks roughly 44.0% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications, as well as to measure the levels of specific bacteria, hormones, antibodies, antigens, and other substances which may exist in the human body, stools, or blood in extremely small concentrations. It sells its products for treating gastrointestinal diseases and food intolerances, as well as various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also involved in the development of InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bo…

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABT) -9% Stryker Corporation (S1YK34) -45% Medtronic plc (MDT) -7% Boston Scientific Corporation (B1SX34) -5% Edwards Lifesciences Corporation (EW) -52% Siemens Healthineers AG (SEMHF) +11%

Frequently asked questions

Is Biomerica, Inc (BMRA) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $0.9800 versus a price of $1.75 — about −44% (overvalued). Model-based estimate, not financial advice.
What is the fair value of BMRA?
Our 21-model fair value for Biomerica, Inc is $0.9800 (as of Jun 25, 2026), built from audited fundamentals. The current price is $1.75.
What is the quality score of BMRA?
Biomerica, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.